These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 31529324

  • 1. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
    Hu Y, Wu Q, Liu B, Cao D, Dong X, Zhang L, Li T, Yang X, Yu H.
    Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
    [Abstract] [Full Text] [Related]

  • 2. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR, Alves D, Santos T, Figueira J, Silva R, Cunha-Vaz JG.
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Optical coherence tomography biomarkers DROL, PROS, SND, hyperreflective walls of foveal cystoid spaces as predictors of central macular thickness and visual acuity in diabetic macular edema treated with intravitreal ranibizumab.
    Sardana A, Singh K, Singh A, Singh VK.
    Indian J Ophthalmol; 2024 May 01; 72(5):722-727. PubMed ID: 38648434
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
    James DGP, Mitkute D, Porter G, Vayalambrone D.
    Asia Pac J Ophthalmol (Phila); 2019 May 01; 8(3):200-205. PubMed ID: 31165603
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D, Sander BA, Monberg TJ, Larsen M, Lund-Andersen H.
    Acta Ophthalmol; 2018 May 01; 96(3):267-278. PubMed ID: 29240306
    [Abstract] [Full Text] [Related]

  • 11. OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema.
    Hsieh YT, Alam MN, Le D, Hsiao CC, Yang CH, Chao DL, Yao X.
    Ophthalmol Retina; 2019 Oct 01; 3(10):826-834. PubMed ID: 31227330
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of the effect of ranibizumab and dexamethasone implant on serous retinal detachment in diabetic macular edema.
    Demircan A, Ozkaya A, Alkin Z, Kemer B, Yesilkaya C, Demir G.
    J Fr Ophtalmol; 2018 Oct 01; 41(8):733-738. PubMed ID: 30213609
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
    Lai K, Huang C, Li L, Gong Y, Xu F, Zhong X, Lu L, Jin C.
    BMC Ophthalmol; 2020 Jun 15; 20(1):229. PubMed ID: 32539744
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.